跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/ISRCTN12117571
ISRCTN12117571已完成未知

Cross-sectional study evaluating the control of risk factors to develop ATHEROsclerosis in the general population of Belgium and Luxembourg treated with at least one antihypertensive agent and a statin.

Servier Benelux0 个研究点目标入组 2,337 人开始时间: 2018年1月16日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
未知
状态
已完成
入组人数
2,337
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • •1. Age = 18 years
  • •2. Confirmed (in medical records) diagnosis of hypertension
  • •3. Confirmed (in medical records) diagnosis of hypercholesterolemia or stable coronary artery disease
  • •4. Prescription of = 1 antihypertensive drug
  • •5. Prescription of a statin

排除标准

  • •Patients hospitalised for cardiovascular diseases in the last 3 months (including revascularization).

研究者

相似试验

尚未招募
Unknown
A Study Regarding the Risk Factors for Lymph node Metastasis of Gastric Adenocarcinoma of Fundic Gland type
JPRN-UMIN000053226Graduate School of Medicine, the University of Tokyo130
已完成
不适用
A cross-sectional study to assess the effects of interprofessional working and inter-unit cooperation on the employee satisfaction in Japanese tertiary hospitals.
JPRN-UMIN000016263Department of education and research in family and community medicine, Mie University Graduate School of Medicine.5,000
进行中（未招募）
不适用
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens - 102-12Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)
EUCTR2004-004774-85-LTBiogen Idec Inc160
进行中（未招募）
不适用
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens - 102-12Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)
EUCTR2004-004774-85-DEBiogen Idec Inc160
进行中（未招募）
不适用
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens - 102-12Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)
EUCTR2004-004774-85-CZBiogen Idec Inc160